GenomeTOX image
GenomeTox will be the one-stop-shop for all animal free human based genotoxicity testing. We developed a patent protected single assay, based on whole genome sequencing of primary human hematopoietic stem cells, which allows for the assessment of all types of genotoxicity. Additionally, we can accurately predict the probability that the assessed compound can cause cancer driver mutations using artificial intelligence and our in vitro data as a training dataset.

Overview of the GenomeTOX pipeline
GenomeTOX team:

  • Annemarie Rietman, PhD, CEO, (Wageningen University, VitalNext b.v., Princess Máxima Center) has several years of experience in the management team of a start-up.
  • Ruben van Boxtel, PhD, CSO, (Hubrecht institute, Princess Máxima Center) is globally recognized for his work in the field of genome biology. 
  • Eline Bertrums, MD, Clinician, (Erasmus University, Princess Máxima Center) studies genomic aberrations and clonal evolution underlying pediatric therapy-related acute myeloid leukemia.
  • Lucca Derks, MSc, Bioinformatician, (Utrecht University, Princess Máxima Center) combines experimental and computational methods to elucidate the clonal evolution of stem cells under chemotherapy treatment.

In January 2022 we enrolled the ProefdierVrij Venture Challenge.  The Proefdiervrij Venture Challenge offered mentorship. During a 3 months-long program six teams were guided through setting up a venture plan, which takes an animal free scientific breakthrough in the life sciences and transformed it into a solid business case.  We were mentored by the team of the GameChanger Challenge BV, who have over 10 years of experience in guiding start-ups to success.

For more information please contact us by sending an e-mail to: